Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$105.18 - $157.98
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.26M
Market Cap
$11.28B
Enterprise Value$13.47B
Total Cash (Recent Filing)$52.22M
Total Debt (Recent Filing)$10.53M
Price to Earnings (P/E)33.6
Beta0.54
Next Earnings
Apr 30, 2025EPS Estimate
0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding99,703,530
10 Day Avg. Volume1,091,968
30 Day Avg. Volume1,258,875
Financial Highlights & Ratios
PEG Ratio1.00
Price to Book (P/B)N/A
Price to Sales (P/S)4.74
Price to Cash Flow (P/CF)11.50
P/FCF Ratio11.50
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.80
Enterprise Value/Ebitda22.07
Forecast
1Y Price Target
$164.50Price Target Upside53.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
---
Bulls Say, Bears Say
Bulls Say
Company GrowthNeurocrine is in a strong position to increase shareholder value with its robust and growing base business.
Product UptakeSurveyed physicians indicated strong uptake of Crenessity over the next 2 years, with potential for a dominant market share.
Sales PotentialBuy-side expectations for Crenessity's first-year sales are surpassing those of the sell-side, suggesting higher sales potential.
Bears Say
Market ExpectationsStreet expectations for Crenessity's first-year sales are considered aggressive.
Short-term PerformanceIngrezza's Q1 to be impacted by a number of headwinds, but prospects for long-term growth remain intact.
---
Ownership Overview
1.08% Insiders
24.91% Mutual Funds
24.62% Other Institutional Investors
20.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $105.17 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $11.28B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Apr 30, 2025 which is in 28 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Feb 06, 2025. The company reported $1 earnings per share for the quarter, missing the consensus estimate of $1.606 by -$0.606.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 0.81.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,703,530 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1 in its last earnings report, missing expectations of $1.606. Following the earnings report the stock price went down -18.53%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
---
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$164.50 (53.74% Upside)
$164.50 (53.74% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.80%
12-Months-Change
Fundamentals
Return on Equity
14.16%
Trailing 12-Months
Asset Growth
15.53%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
---
NBIX Company Deck
---
NBIX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Neurocrine's strong performance in 2024 with record sales for INGREZZA and the successful launch of Quinicity. While there are challenges, such as increased competitive pressure and a measured launch for Quinicity, the company is taking proactive steps to address these issues. The overall sentiment is cautiously optimistic with a focus on growth and expansion in the neuroscience field.Read More>---
NBIX Stock 12 Month Forecast
Average Price Target
$164.50
▲(53.74% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
17/29 ratings generated profit
1 Year Average Return
+8.57%
reiterated a buy rating 5 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +8.57% per trade.
---